Annual EBITDA
-$4.31 M
+$94.58 M+95.64%
December 31, 2023
Summary
- As of February 7, 2025, CTMX annual EBITDA is -$4.31 million, with the most recent change of +$94.58 million (+95.64%) on December 31, 2023.
- During the last 3 years, CTMX annual EBITDA has risen by +$73.66 million (+94.47%).
- CTMX annual EBITDA is now at all-time high.
Performance
CTMX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
$4.54 M
+$12.53 M+156.80%
September 30, 2024
Summary
- As of February 7, 2025, CTMX quarterly EBITDA is $4.54 million, with the most recent change of +$12.53 million (+156.80%) on September 30, 2024.
- Over the past year, CTMX quarterly EBITDA has increased by +$933.00 thousand (+25.87%).
- CTMX quarterly EBITDA is now -62.55% below its all-time high of $12.12 million, reached on March 31, 2024.
Performance
CTMX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
$8.55 M
+$933.00 K+12.25%
September 30, 2024
Summary
- As of February 7, 2025, CTMX TTM EBITDA is $8.55 million, with the most recent change of +$933.00 thousand (+12.25%) on September 30, 2024.
- Over the past year, CTMX TTM EBITDA has increased by +$21.64 million (+165.33%).
- CTMX TTM EBITDA is now -33.57% below its all-time high of $12.87 million, reached on March 31, 2024.
Performance
CTMX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CTMX EBITDA Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +95.6% | +25.9% | +165.3% |
3 y3 years | +94.5% | +25.9% | +165.3% |
5 y5 years | +94.3% | +25.9% | +165.3% |
CTMX EBITDA Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | at high | +96.2% | -62.5% | +107.8% | -33.6% | +105.8% |
5 y | 5-year | at high | +96.9% | -62.5% | +106.7% | -33.6% | +105.8% |
alltime | all time | at high | +96.9% | -62.5% | +106.7% | -33.6% | +105.8% |
CytomX Therapeutics EBITDA History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | $4.54 M(-156.8%) | $8.55 M(+12.2%) |
Jun 2024 | - | -$7.99 M(-165.9%) | $7.62 M(-40.8%) |
Mar 2024 | - | $12.12 M(<-9900.0%) | $12.87 M(-398.7%) |
Dec 2023 | -$4.31 M(-95.6%) | -$120.00 K(-103.3%) | -$4.31 M(-67.1%) |
Sep 2023 | - | $3.61 M(-231.7%) | -$13.09 M(-71.4%) |
Jun 2023 | - | -$2.74 M(-45.9%) | -$45.78 M(-36.8%) |
Mar 2023 | - | -$5.06 M(-43.2%) | -$72.49 M(-26.7%) |
Dec 2022 | -$98.89 M(-12.7%) | -$8.90 M(-69.4%) | -$98.89 M(-33.1%) |
Sep 2022 | - | -$29.09 M(-1.2%) | -$147.88 M(+5.1%) |
Jun 2022 | - | -$29.44 M(-6.4%) | -$140.76 M(+8.4%) |
Mar 2022 | - | -$31.46 M(-45.7%) | -$129.84 M(+14.6%) |
Dec 2021 | -$113.34 M(+45.4%) | -$57.89 M(+163.6%) | -$113.34 M(+11.7%) |
Sep 2021 | - | -$21.96 M(+18.5%) | -$101.49 M(+8.2%) |
Jun 2021 | - | -$18.53 M(+23.9%) | -$93.78 M(+3.3%) |
Mar 2021 | - | -$14.95 M(-67.5%) | -$90.76 M(+16.4%) |
Dec 2020 | -$77.97 M(-43.9%) | -$46.05 M(+223.3%) | -$77.97 M(-21.5%) |
Sep 2020 | - | -$14.24 M(-8.2%) | -$99.27 M(-9.8%) |
Jun 2020 | - | -$15.52 M(+619.7%) | -$110.07 M(-12.0%) |
Mar 2020 | - | -$2.16 M(-96.8%) | -$125.12 M(-9.9%) |
Dec 2019 | -$138.88 M | -$67.36 M(+169.0%) | -$138.88 M(+43.4%) |
Sep 2019 | - | -$25.04 M(-18.1%) | -$96.83 M(+2.5%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Jun 2019 | - | -$30.57 M(+92.1%) | -$94.46 M(+23.2%) |
Mar 2019 | - | -$15.91 M(-37.1%) | -$76.68 M(+0.9%) |
Dec 2018 | -$75.99 M(+81.1%) | -$25.31 M(+11.7%) | -$75.99 M(+55.5%) |
Sep 2018 | - | -$22.67 M(+77.2%) | -$48.86 M(+33.0%) |
Jun 2018 | - | -$12.79 M(-15.9%) | -$36.74 M(-24.9%) |
Mar 2018 | - | -$15.22 M(-935.7%) | -$48.95 M(+16.7%) |
Dec 2017 | -$41.95 M(-26.6%) | $1.82 M(-117.3%) | -$41.95 M(-26.2%) |
Sep 2017 | - | -$10.55 M(-57.8%) | -$56.84 M(-6.5%) |
Jun 2017 | - | -$25.00 M(+204.2%) | -$60.77 M(+22.6%) |
Mar 2017 | - | -$8.22 M(-37.1%) | -$49.58 M(-12.5%) |
Dec 2016 | -$57.19 M(+76.4%) | -$13.07 M(-9.7%) | -$56.68 M(+4.2%) |
Sep 2016 | - | -$14.47 M(+4.8%) | -$54.38 M(+7.2%) |
Jun 2016 | - | -$13.81 M(-9.8%) | -$50.75 M(+20.8%) |
Mar 2016 | - | -$15.32 M(+42.1%) | -$42.03 M(+29.6%) |
Dec 2015 | -$32.43 M(+11.7%) | -$10.78 M(-0.6%) | -$32.43 M(+24.3%) |
Sep 2015 | - | -$10.84 M(+113.0%) | -$26.09 M(+40.8%) |
Jun 2015 | - | -$5.09 M(-10.9%) | -$18.53 M(+37.9%) |
Mar 2015 | - | -$5.71 M(+28.5%) | -$13.44 M(+74.0%) |
Dec 2014 | -$29.03 M(+104.1%) | -$4.45 M(+35.7%) | -$7.72 M(+135.7%) |
Sep 2014 | - | -$3.28 M | -$3.28 M |
Dec 2013 | -$14.22 M | - | - |
FAQ
- What is CytomX Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for CytomX Therapeutics?
- What is CytomX Therapeutics annual EBITDA year-on-year change?
- What is CytomX Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for CytomX Therapeutics?
- What is CytomX Therapeutics quarterly EBITDA year-on-year change?
- What is CytomX Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for CytomX Therapeutics?
- What is CytomX Therapeutics TTM EBITDA year-on-year change?
What is CytomX Therapeutics annual EBITDA?
The current annual EBITDA of CTMX is -$4.31 M
What is the all time high annual EBITDA for CytomX Therapeutics?
CytomX Therapeutics all-time high annual EBITDA is -$4.31 M
What is CytomX Therapeutics annual EBITDA year-on-year change?
Over the past year, CTMX annual EBITDA has changed by +$94.58 M (+95.64%)
What is CytomX Therapeutics quarterly EBITDA?
The current quarterly EBITDA of CTMX is $4.54 M
What is the all time high quarterly EBITDA for CytomX Therapeutics?
CytomX Therapeutics all-time high quarterly EBITDA is $12.12 M
What is CytomX Therapeutics quarterly EBITDA year-on-year change?
Over the past year, CTMX quarterly EBITDA has changed by +$933.00 K (+25.87%)
What is CytomX Therapeutics TTM EBITDA?
The current TTM EBITDA of CTMX is $8.55 M
What is the all time high TTM EBITDA for CytomX Therapeutics?
CytomX Therapeutics all-time high TTM EBITDA is $12.87 M
What is CytomX Therapeutics TTM EBITDA year-on-year change?
Over the past year, CTMX TTM EBITDA has changed by +$21.64 M (+165.33%)